Progressive efficacy improvements with quarterly intravenous ibandronate injections: The DIVA study long term extension

被引：0
|
作者：
Czerwinski, E.
Langdahl, B.
Stepan, J.
Grant, R.
Neate, C.
Bianchi, G.
机构：
[1] Krakow Med Ctr, Dept Med, Krakow, Poland
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Charles Univ Prague, Dept Internal Med, Prague, Czech Republic
[4] Hoffmann La Roche Inc, Nutley, NJ USA
[5] Roche Prod Ltd, Pharma Dev Med Biostat, Welwyn Garden City AL7 3AY, Herts, England
[6] Osped Coletta, Div Rheumatol, Genovese, Italy
来源：
CALCIFIED TISSUE INTERNATIONAL | 2007年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [21] Consistent bone mineral density gains with intravenous ibandronate injections: Results from the DIVA study.
    Emkey, R
    Halse, J
    Kruse, HP
    Hughes, C
    Ward, P
    Masanauskaite, D
    Recker, RR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S285 - S285
  • [22] Intermittent intravenous ibandronate injections are at least as effective as daily oral ibandronate: 1-Year DIVA results
    Lewiecki, M
    Zaidi, M
    Drezner, M
    Recknor, C
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 802 - 802
  • [23] Safety and tolerability of intravenous ibandronate injections: DIVA 1-year analysis.
    Drezner, MK
    Ste-Marie, LG
    Nuti, R
    Benhamou, C
    Leigh, C
    Ward, P
    Masanauskaite, D
    Lewiecki, EM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S396 - S396
  • [24] Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study
    Recker, Robert R.
    Ste-Marie, Louis-George
    Langdahl, Bente
    Czerwinski, Edward
    Bonvoisin, Bernard
    Masanauskaite, Daiva
    Rowell, Lucy
    Felsenberg, Dieter
    BONE, 2010, 46 (03) : 660 - 665
  • [25] Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies
    P. D. Miller
    R. R. Recker
    S. Harris
    S. Silverman
    D. Felsenberg
    J. Reginster
    B-M. Day
    C. Barr
    D. Masanauskaite
    Osteoporosis International, 2014, 25 : 349 - 357
  • [26] Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies
    Miller, P. D.
    Recker, R. R.
    Harris, S.
    Silverman, S.
    Felsenberg, D.
    Reginster, J.
    Day, B-M
    Barr, C.
    Masanauskaite, D.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (01) : 349 - 357
  • [27] Renal safety of intravenous ibandronate injections in postmenopausal osteoporosis (PMO): DIVA 1-year results
    Civitelli, R
    Emkey, R
    Bolognese, M
    Recker, R
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 795 - 795
  • [28] Efficacy of ibandronate: a long term confirmation
    Baminger, Helmut
    JOURNAL FUR MINERALSTOFFWECHSEL, 2010, 17 (04): : 173 - 174
  • [29] Efficacy of ibandronate: a long term confirmation
    Di Munno, Ombretta
    Delle Sedie, Andrea
    CLINICAL CASES IN MINERAL AND BONE METABOLISM, 2010, 7 (01) : 23 - 26
  • [30] Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
    P. D. Miller
    R. R. Recker
    J.-Y. Reginster
    B. J. Riis
    E. Czerwinski
    D. Masanauskaite
    A. Kenwright
    R. Lorenc
    J. A. Stakkestad
    P. Lakatos
    Osteoporosis International, 2012, 23 : 1747 - 1756
12345